RANCHO CORDOVA, Calif., April 2 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. , a leading supplier of innovative products and services that process and store adult stem cells, said today that its devices will be the subject of several scientific abstracts to be presented at the International Stem Cell Therapy (ISCT) 2009 Annual Meeting in San Diego, May 3-6.
The abstracts will cover the efficacy of the Company's BioArchive(R) System, MarrowXpress(TM) (MXP(TM)) and Res-Q(TM) devices in the processing of stem cells from cord blood and bone marrow. Additional abstracts will address the impact of sterilization practices on stem cell processing, and findings regarding the collection of equine stem cells. The Company will also be demonstrating its products at booth #200.
"We are delighted to have the opportunity to contribute to this leading stem cell industry conference. We believe this forum provides us the opportunity for the industry to be aware of the value of our devices in the collection and storage of stem cells from cord blood and bone marrow, as well as our ability to bring innovation to the market through devices such as the MXP and Res-Q," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.
The abstracts to be presented at the ISCT include:
"These abstracts are significant as they not only demonstrate the efficacy of our devices, but also with presentations such as our review of sterilization practices, demonstrate ThermoGenesis' goal of advancing the field of cell therapy," said John Chapman, PhD, Vice President of Scientific Affairs who directs the Company's clinical programs. "We look forward to interacting with leading clinicians and solution providers in the stem cell sector at the upcoming ISCT and identifying new opportunities for the use of our cell processing technology," he added.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
CONTACT: Investor Relations of ThermoGenesis Corp., +1-916-858-5107,
ir@thermogenesis.com
Web site: http://www.thermogenesis.com/
